Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Louisiana Prior Auth Form…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - LouisianaPolicy N/A

    Prior authorization request form for prescription and provider-administered medications (including opioids)

    Customize your policy alerts

    Sign up for all blue cross blue shield - louisiana policy alerts

    Know when blue cross blue shield - louisiana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a prior authorization submission form used by prescribers to request coverage for prescription drugs and provider-administered medications (including opioid-specific attestation) for Blue Cross and Blue Shield of Louisiana members. It captures prescriber, patient, clinical, and drug administration details needed to process authorization.

    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyPrior authorization request form for prescription and provider-administered medications (including opioids)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit complete prior authorization with drug details, diagnosis (ICD-10), required documentation, and opioid attestation when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    I-VIIform sections present

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Present
    opioid attestations
    HCPCS/NDCprovider-administered coding
    IncludedMME checks

    Coverage and Authorization Criteria

    Authorization criteria

    Coverage evaluation requires completion of the following information and attestations

    Submission completeness: Prescriber and patient demographic fields, requested drug details (name, strength, dosage form, route, quantity, days' supply), and expected therapy duration must be provided.

    See Section IV

    Clinical justification: Primary diagnosis and ICD-10 code, date diagnosed, pertinent lab values, and documentation of prior pharmacologic and non-pharmacologic treatments (with dates and response) must be provided.

    See Sections V and VII

    Provider-administered coding: If drug is provider-administered, HCPCS/CPT-4 code, NDC and dose per administration must be provided and site of administration identified.

    See Section IV

    Opioid-specific criteria: For opioid requests, prescriber must attest to attestation items A-L (assessment, screening, PMP access, treatment plan, established failure criteria, discussion of benefits/harms, opioid treatment agreement where applicable, requirement for around-the-clock therapy, prior short-acting opioid trial of at least two weeks, not for acute/PRN use, and review of product prescribing information), report cumulative daily MME, and indicate if quantity or MME exceed allowed limits with justification if so.

    See Sections VI and VII and opioid attestation list

    The form does not list any separate, explicit clinical exclusions beyond the opioid-specific attestations. However, for opioid long-acting therapy the prescriber must attest to items A–L in the opioid attestation section. Notably, attestations J and K exclude opioids intended for acute pain or for as‑needed (PRN) use from consideration as long‑acting opioid therapy.

    Requests for long‑acting opioid medications must not be for treatment of acute pain, mild pain, or for as‑needed (PRN) analgesia. The prescriber must attest that the medication has not been prescribed to treat acute pain, mild pain, or pain not expected to persist (attestation J) and that it has not been prescribed for as‑needed use (attestation K). These attestations establish that acute/PRN indications are not appropriate for long‑acting opioid therapy.

    Billing and Diagnosis Codes

    Provider-administered drug codesmixed
    HCPCS/CPT-4Field for provider-administered drug procedure/billing code
    NDCField for product NDC number
    Diagnosis codesICD-10
    ICD-10Primary and secondary diagnosis code fields
    inv-06: Cumulative daily MME
    Field nameCumulative daily MME
    Form locationSection VI — This Section For Opioid Medications Only
    Related checksForm asks whether cumulative daily MME exceeds the daily max MME allowed and requests justification if yes

    Provider Submission Requirements and Documentation

    Prior Authorization

    Prior Authorization Submission Requirements

    Prior authorization is required for many drug requests. Submit the requested drug name, strength, dosage form, route, total quantity, days' supply, dosage interval/directions for use, and expected therapy duration or start date. Indicate whether this is a new therapy (initial request) or a continuation/reauthorization.

    • Requested drug name, strength, dosage form, route
    • Quantity, Days' supply, Dosage interval/Directions for use
    • Expected therapy duration / Start date
    • Indicate New therapy vs Continuation/Reauthorization
    Billing Rule

    Missing Coding for Provider‑Administered Drugs

    Policy Background

    This form is used to collect the clinical and administrative information required to evaluate medical necessity for drug therapies, including controlled substances. For opioid requests the form captures a series of required attestations (A–L) addressing assessment, screening, PMP access, treatment plan, opioid trial history, agreement on file, and indication for around‑the‑clock therapy, and it requires the prescriber’s signature confirming the information provided.

    Definitions and Key Terms

    inv-14: Provider-administered drug
    DefinitionProvider-administered drug: drug administered by a provider with fields to capture HCPCS/CPT-4 code, NDC number, dose per administration, and other codes
    Coding requiredHCPCS/CPT-4 code and NDC# fields must be completed for provider-administered drugs
    Dose informationDose per administration must be provided on the form
    inv-15: Opioid-specific requirements
    Daily MME reportingPrescriber must report cumulative daily MME on the form (Section VI)
    MME exceedance checkForm asks whether cumulative daily MME exceeds the daily max MME allowed and requests justification if it does

    Initial Therapy Requirements

    Initial therapy

    Initial requests must document prior treatments and rationale if step therapy will be bypassed

    Initial therapy details: Indicate therapy is new/initial, provide planned start date and expected therapy duration, and document prior treatment history including pharmacologic and non-pharmacologic therapies with dates and response.

    See Section IV and VII

    Step therapy exception rationale: If there is clinical evidence or patient history that prerequisite (step) medication(s) will be ineffective or cause an adverse reaction, select 'Yes' and provide an explanation in Section VIII of the form.

    See Section VII

    Opioid-specific initial requirements: For initiation of long-acting opioid therapy, document at least a two-week trial of short-acting opioids for this condition (enter drug(s), dose, duration, and dates in the pharmacologic treatment section) and complete attestation items A-L.

    See Section VI (attestation I) and Section VII

    Continuation / Reauthorization Criteria

    Continuation therapy

    Continuation/reauthorization requests require current therapy designation and prior dosing history

    Continuation details: Indicate that the request is a continuation of therapy/reauthorization and provide current dose, dates started (and stopped if applicable), and response to therapy.

    See Section IV and VII

    Prior dosing history: Provide prior dosing history and dates for pharmacologic treatments used for this diagnosis, including any short-acting opioid trials if relevant to ongoing long-acting opioid therapy.

    See Section VII

    Opioid continuation requirements: For ongoing opioid therapy, report cumulative daily MME, indicate whether the requested quantity or cumulative MME exceeds allowed maximums and provide justification if limits are exceeded, and ensure attestation items A-L remain satisfied or explain deviations.

    See Sections VI and VII

    Step Therapy Exceptions

    RequirementProvider action / form fieldNotes
    Step therapy bypass explanation requiredForm asks: 'Is there clinical evidence or patient history that suggests the use of the plan's pre-requisite medication(s), e.g. step medications, will be ineffective or cause an adverse reaction to the patient? ____Yes ____No' — If Yes, prescriber must 'please explain in Section VIII below.'Prescriber must provide clinical rationale in Section VIII; absence of explanation may result in inability to process request or denial if step therapy is required.

    Administration Site and Facility Information

    Note

    Identify site of care and servicing provider/NPI if offsite

    Indicate on the form whether the patient will receive the drug in the physician's office; if No, provide the servicing provider or facility name and NPI.

    • Check Yes/No for administration in physician's office
    • If No, list servicing provider/facility name and NPI
    Policy Summary
    PayerBlue Cross Blue Shield - Louisiana
    PolicyPrior authorization request form for prescription and provider-administered medications (including opioids)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit complete prior authorization with drug details, diagnosis (ICD-10), required documentation, and opioid attestation when applicable.
    SourceLink
    On This Page
    Coverage and Authorization CriteriaBilling and Diagnosis CodesProvider Submission Requirements and DocumentationPolicy BackgroundDefinitions and Key TermsInitial Therapy RequirementsContinuation / Reauthorization CriteriaStep Therapy ExceptionsAdministration Site and Facility Information

    For provider-administered drugs, include HCPCS/CPT-4 code and/or NDC. Provide the dose per administration and any other applicable codes. If the patient will not receive the drug in the prescriber's office, include the servicing provider/facility name and NPI. Omission of HCPCS/CPT-4, NDC, or dose-per-administration may result in rejection or processing delays.

    • HCPCS/CPT-4 code (required when applicable)
    • NDC# (if available) and Dose per administration
    • Other applicable codes
    • If not administered in prescriber's office, provide servicing provider/facility name and NPI
    Documentation Required

    Required Clinical Documentation

    Provide complete clinical documentation to support medical necessity. Incomplete or missing primary diagnosis, ICD-10 code, dates diagnosed, or pertinent laboratory values may prevent processing of the request.

    • Patient demographics and identifiers (name, DOB, member ID)
    • Primary diagnosis relevant to this request with ICD-10 code and date diagnosed
    • Secondary diagnosis (if applicable) with ICD-10 code and date diagnosed
    • Pertinent laboratory values and dates (attach results or list below)
    • For postoperative pain: date of surgery
    Documentation Required

    Opioid-Specific Documentation

    For opioid medication requests include opioid-specific documentation: whether the requested quantity exceeds the plan's max quantity limit and justification if it does; cumulative daily morphine milligram equivalent (MME) and justification if it exceeds the plan's daily max MME. The prescriber must complete attestations A–L (pain/function assessment, substance use screening, PMP checks, treatment plan, opioid agreement, prior short-acting opioid trial, not for acute/PRN use, etc.). If any attestation (A–L) is 'No', provide an explanation.

    • Does requested quantity exceed plan max quantity limit? Yes/No — if Yes, provide justification
    • Cumulative daily MME — value and indicate if it exceeds plan max MME (Yes/No). If Yes, provide justification
    • Prescriber attestations A–L (see checklist): pain/function assessment; substance abuse screening; PMP access; treatment plan; failure criteria; risks/benefits discussed; opioid treatment agreement; need for continuous around-the-clock therapy; prior short-acting opioid trial; not for acute/mild/short-term pain; not PRN; prescriber reviewed product labeling
    • If any attestation is 'No', explain in the provided space
    Step Therapy

    Pharmacologic and Non‑Pharmacologic Treatment History / Step Therapy Exception Rationale

    List prior and current pharmacologic and non-pharmacologic treatments for this diagnosis, including drug name, strength, frequency, dates started/stopped (or approximate duration), response and reason for discontinuation. Include drug allergies, height/weight if applicable. Indicate whether there is clinical evidence or patient history to support bypassing step-therapy (pre-requisite) medications and provide an explanation if yes.

    • Pharmacologic & non-pharmacologic treatments: drug name, strength, frequency, dates/duration, response/reason
    • Drug allergies
    • Height and weight (if applicable)
    • Does patient history support exception to step-therapy? Yes/No — if Yes, explain
    Denial Risk

    Incomplete Clinical Information

    Incomplete clinical information — missing primary diagnosis, ICD-10 code, dates, or pertinent lab results may prevent or delay processing of the request. Ensure all required fields are completed and attach relevant documents or test results.

    • Ensure primary diagnosis, ICD-10 code, and date diagnosed are provided
    • Provide pertinent laboratory values with test names and dates
    • Attach supporting documentation when applicable (operative reports, notes, prior therapy records)
    Quantity exceedanceForm asks whether the quantity requested exceeds the max quantity limit allowed and requests justification if yes
    Opioid attestation elementsPrescriber must attest to items A–L including pain assessment, screening for substance abuse, PMP access, treatment plan, opioid trial details, opioid treatment agreement, indication for around-the-clock therapy, not prescribed for acute/PRN use, and review of prescribing information